Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)

BACKGROUND: The bispecific monoclonal antibody emicizumab bridges activated factor IX and factor X, mimicking the cofactor function of activated factor VIII (FVIII), restoring hemostasis. OBJECTIVES: The Phase 3b STASEY study was designed to assess the safety of emicizumab prophylaxis in people with...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez‐Yuste, Víctor, Peyvandi, Flora, Klamroth, Robert, Castaman, Giancarlo, Shanmukhaiah, Chandrakala, Rangarajan, Savita, García Chavez, Jaime, Martinez, Raul, Kenet, Gili, Alzahrani, Hazaa, Robson, Susan, Schmitt, Christophe, Kiialainen, Anna, Meier, Oliver, Ozelo, Margareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663319/
https://www.ncbi.nlm.nih.gov/pubmed/36397934
http://dx.doi.org/10.1002/rth2.12837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663319/
https://www.ncbi.nlm.nih.gov/pubmed/36397934
http://dx.doi.org/10.1002/rth2.12837

Ejemplares similares